Dennis J. Carlo, Ph.D. - President, Chief Executive Officer
Dr. Carlo is a co-founder of Adamis Pharmaceuticals Corporation and has served as its President and Chief Executive officer since October 2006. Dr. Carlo has extensive biotechnology research and development experience. At Hybritech Inc., the first biotechnology company in San Diego, he served as Vice President of Research and Development and Therapeutic Manufacturing. There, he managed a successful program to carry out research and development in the areas of monoclonal antibody and cancer therapy. After Hybritech was acquired by Eli Lilly & Co in 1985, Dr. Carlo, along with Dr. Jonas Salk, James Glavin and Kevin Kimberlin, founded The Immune Response Corporation, a public company, where he served in various capacities including Chief Scientific Officer, COO and President and Chief Executive Officer. At The Immune Response Corporation, he established programs in Autoimmunity, Gene Therapy and HIV and led the product development in successful clinical trials. In 1991, while at Immune Response, Dr. Carlo was awarded “Entrepreneur of the Year” by Ernst & Young LLP. From 2003 to 2006, He served as president of Telos Pharmaceuticals, a private biotechnology company. Early in his career, as Director of Developmental and Basic Cellular Immunology and Director of Bacterial Vaccines and Immunology at Merck & Co., he oversaw research and product development for PNEUMOVAX (multi-valent polysaccharide vaccine), MENINGOVAX A, MENINGOVAX C, MENINGOVAX A-C, and H. influenzae type b, and also directed a multi-disciplinary task force whose goal was the development of novel adjuvants. Dr. Carlo received a B.S. degree in Microbiology from Ohio State University and has a Ph.D. in Immunology and Medical Microbiology from Ohio State University. He is named on 23 patents and has authored over 225 articles and abstracts in the field of Immunology.
David C. Benedicto – Chief Financial Officer
Mr. Benedicto has more than two decades of experience operating in finance roles at public and private companies. Since joining Adamis in late 2014, he has served as Controller and then as Chief Accounting Officer. He previously held a senior accounting manager role at Trius Therapeutics, Inc. prior to the business being acquired. He has also held controller positions and led finance functions at HERC Products, Inc. and BAE Systems Inc. Mr. Benedicto is a CPA and a CMA (Certified Management Accountant) and holds a bachelor’s degree in Accounting from the University of Saint La Salle and a Master of Business Administration from the University of Redlands.
David J. Marguglio - Senior Vice President, Chief Business Officer
Ronald B. Moss, M.D. – Chief Medical Officer
Dr. Moss joined Adamis as Chief Medical Officer in February 2017. Prior to joining Adamis, Dr. Moss worked at Ansun Biopharma as CEO and President from October 2012 to February 2017 and as interim CEO from October 2011 to October 2012. Dr. Moss served as Executive Vice President of Clinical Development & Medical Affairs at NexBio from January 2009- October 2011. From June 2006 to January 2009 Dr. Moss served as the Vice President of Clinical Development at Vical Inc. During January 2004- March 2006 he served as the Vice President of Medical Affairs at Telos Pharmaceuticals. Dr. Moss served as the Senior Director of Worldwide Regulatory Affairs for Vaccines/Biologics at Merck and Company from January 2003- January 2004. Dr. Moss joined The Immune Response Corp. in January 1994 as Medical Director and advanced through positions of increasing responsibility and served as the interim President and Chief Executive Officer from August 2002 to January 2003. From July 1993 to January 1994 Dr. Moss served as Assistant Medical Director at Immunization Products Ltd., a joint venture between Rhone-Poulenc Rorer and Immune Response. Dr. Moss trained in Pediatrics at SUNY Stony Brook and completed his Fellowship in Allergy and Clinical Immunology at the National Institutes of Health, and is board certified in allergy & immunology. He is Fellow of the American Academy of Allergy Asthma and Immunology (FAAAI) and a Fellow of the American College of Allergy, Asthma, and Immunology (FCAAI). Dr. Moss is a voluntary faculty member at UCSD School of Medicine Department of Medicine. Dr. Moss earned his M.D. degree at the Chicago Medical School, Rosalind Franklin University of Medicine and Science and his bachelor’s degree from the State University of New York at Stony Brook.
Thomas Moll, Ph.D. - Vice President of Research
Dr. Moll has close to 20 years of experience in both academic and industrial preclinical research and development in the areas of inflammation, immunology and cancer biology. As part of his work, Dr. Moll has gained extensive experience in the generation, production and use of biologics, including protein/Fc chimeras, antibodies and gene therapeutics. After concluding his diploma studies in Biochemistry at the Biocenter, University of Basel, Switzerland, Dr. Moll received his doctorate degree in Genetics and Biochemistry “With Honours” from the University of Vienna, Austria. Subsequent to his work with Boehringer Ingelheim and Sandoz (now Novartis) in Vienna, Austria, Dr. Moll served as Assistant Professor at the University of Muenster, Germany, before joining Cardion AG, a privately held German biotech company. At Cardion, (then Cardiogene) Dr. Moll was initially in charge of the company’s preclinical cardiovascular gene therapy program, before taking over the responsibility for Cardion’s immunology programs as Vice President of Immunology. In this function he supervised the research and preclinical development of several protein/Fc fusion proteins, including CRB-15, an antagonist IL-15/Fc fusion protein. In 2003, Roche Pharmaceuticals licensed this protein for clinical development in various autoimmune disease indications. Before joining the Adamis management team, Dr. Moll was responsible for all research and development activities at Telos Pharmaceuticals. Dr. Moll serves as Editor of the Journal of Immune Based Therapies and has been a member of the European Society of Gene Therapy, the North American Vascular Biology Organization, the American Association of Immunologists, and the American Society of Transplantation.